Brinex-M, eye drops 1% 5 ml

Increased intraocular pressure is the main risk factor for optic nerve damage and narrowing of the visual field.

Brinzolamide is an inhibitor of carboanhydrase II. Due to inhibition of carboanhydrase II formation of bicarbonate ions is slowed down with subsequent reduction of sodium transport in the fluid which leads to decrease of intraocular fluid production in the ciliary body of the eye. This results in a decrease in intraocular pressure (IOP).

Pharmacokinetics:
When applied topically, brinzolamide penetrates the systemic bloodstream. Brinzolamide is adsorbed in erythrocytes as a result of selective binding. A metabolite, N-dezethyl brinzolamide, is formed, which also binds to carboangidase and accumulates in erythrocytes. In the presence of brinzolamide, the metabolite binds primarily to carboanhydrase I.

In plasma concentrations of brinzolamide and its metabolite are below the limit of quantification (<10 ng/ml). The elimination half-life is 111 days. Binding to plasma proteins is about 60%. Brinzolamide is mainly excreted unchanged in the urine. The main metabolite (N-dezethylbrinzolamide) and low concentrations of other metabolites (N-desmethoxypropyl and O-desmethyl) are also detected in the urine.

Indications

Lowering intraocular pressure in:

As monotherapy in patients who do not respond to β-blockers or in patients for whom β-blockers are contraindicated.

As adjunctive therapy to β-blockers or prostaglandin analogues.

Active ingredient

Composition

Composition of 1 ml of the drug:

Active ingredient: brinzolamide 10 mg

Excipients:

benzalkonium chloride 0.1 mg,

dinatrium edetate dihydrate 0.1 mg,

sodium chloride 2.5 mg,

tiloxapol 0.25 mg,

mannitol 33.0 mg,

carbomer (974P) 4.2 mg,

5M sodium hydroxide solution to pH 7.5,

1M hydrochloric acid solution to pH 7.5,

water for injection to 1 ml.

How to take, the dosage

Interaction

Special Instructions

Contraindications

Hypersensitivity to the active ingredient or any of the excipients;

Hypersensitivity to sulfonamides;

severe renal insufficiency;

hyperchloremic acidosis.

Caution should be exercised when using the drug in patients with risk of renal failure because of the possible development of metabolic acidosis.

The effect of brinzolamide on corneal endothelial function in patients with corneal disorders (especially in patients with low endothelial cell counts) has not been studied. Therefore, close monitoring of these patients is recommended when using brinzolamide.

Caution should be exercised when treating patients with pseudoexfoliative glaucoma or pigmentary glaucoma, and close monitoring of IOP is recommended.

The use of the drug has not been studied in patients with closed-angle glaucoma, with severe liver disease, so this patient should be prescribed with caution.

Side effects

Overdose

There are no reports of overdose symptoms when administered topically. When administering the drug orally there may be electrolyte imbalance, development of acidosis, as well as disorders of the nervous system.

The electrolyte levels (especially potassium) and pH of the blood should be monitored.

Pregnancy use

Similarities